Merck KGaA (MRK) Given a €93.00 Price Target at Credit Suisse Group

Share on StockTwits

Merck KGaA (FRA:MRK) received a €93.00 ($108.14) price target from investment analysts at Credit Suisse Group in a research note issued on Tuesday, October 23rd. The firm currently has a “neutral” rating on the healthcare company’s stock. Credit Suisse Group’s target price suggests a potential downside of 4.75% from the company’s current price.

A number of other research firms have also commented on MRK. Kepler Capital Markets set a €105.00 ($122.09) price objective on Merck KGaA and gave the company a “buy” rating in a research note on Friday, October 19th. Commerzbank set a €100.00 ($116.28) price objective on Merck KGaA and gave the company a “buy” rating in a research note on Wednesday, October 17th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Merck KGaA in a research report on Wednesday, October 17th. UBS Group set a €115.00 ($133.72) target price on Merck KGaA and gave the stock a “buy” rating in a research report on Wednesday, October 17th. Finally, Goldman Sachs Group set a €92.00 ($106.98) target price on Merck KGaA and gave the stock a “neutral” rating in a research report on Wednesday, October 17th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and seven have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of €98.00 ($113.95).

Shares of MRK traded up €4.14 ($4.81) during trading hours on Tuesday, reaching €97.64 ($113.53). 779,281 shares of the company traded hands. Merck KGaA has a fifty-two week low of €76.60 ($89.07) and a fifty-two week high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Article: How can you know how many shares are floating?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.